Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

NCT00458120 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Dengue Hemorrhagic Fever

Interventions

BIOLOGICAL: rDEN1delta30
BIOLOGICAL: rDEN2/4delta30(ME)
BIOLOGICAL: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]